A Decade of Cerebrospinal Fluid Biomarkers for Alzheimer’s Disease in Belgium
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A Decade of Cerebrospinal Fluid Biomarkers for Alzheimer’s Disease in Belgium
Authors
Keywords
-
Journal
JOURNAL OF ALZHEIMERS DISEASE
Volume 54, Issue 1, Pages 383-395
Publisher
IOS Press
Online
2016-08-17
DOI
10.3233/jad-151097
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The utility of α-synuclein as biofluid marker in neurodegenerative diseases: a systematic review of the literature
- (2016) Anja Hviid Simonsen et al. Biomarkers in Medicine
- Assessing the commutability of reference material formats for the harmonization of amyloid-β measurements
- (2016) Maria Bjerke et al. CLINICAL CHEMISTRY AND LABORATORY MEDICINE
- Diagnostic Impact of Cerebrospinal Fluid Biomarker (Pre-)Analytical Variability in Alzheimer’s Disease
- (2016) Ellis Niemantsverdriet et al. JOURNAL OF ALZHEIMERS DISEASE
- Clinical utility and applicability of biomarker-based diagnostic criteria for Alzheimer’s disease: a BeDeCo survey
- (2015) Jean-Christophe Bier et al. ACTA NEUROLOGICA BELGICA
- Importance and Impact of Preanalytical Variables on Alzheimer Disease Biomarker Concentrations in Cerebrospinal Fluid
- (2015) N. Le Bastard et al. CLINICAL CHEMISTRY
- Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia
- (2015) Willemijn J. Jansen et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Cerebrospinal Fluid P-Tau181P: Biomarker for Improved Differential Dementia Diagnosis
- (2015) Hanne Struyfs et al. Frontiers in Neurology
- TDP-43 as a possible biomarker for frontotemporal lobar degeneration: a systematic review of existing antibodies
- (2015) Joery Goossens et al. Acta Neuropathologica Communications
- The clinical use of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: A consensus paper from the Alzheimer's Biomarkers Standardization Initiative
- (2014) José Luis Molinuevo et al. Alzheimers & Dementia
- Assessment of CSF Aβ42 as an aid to discriminating Alzheimer's disease from other dementias and mild cognitive impairment: A meta-analysis of 50 studies
- (2014) Wei Tang et al. JOURNAL OF THE NEUROLOGICAL SCIENCES
- Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria
- (2014) Bruno Dubois et al. LANCET NEUROLOGY
- Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases
- (2014) Alberto Lleó et al. Nature Reviews Neurology
- CSF biomarker variability in the Alzheimer's Association quality control program
- (2013) Niklas Mattsson et al. Alzheimers & Dementia
- Clinical indications for analysis of Alzheimer's disease CSF biomarkers
- (2013) S. Engelborghs REVUE NEUROLOGIQUE
- The role of CSF biomarkers in the diagnostic work-up of mixed vascular-degenerative dementia
- (2012) Sebastiaan Engelborghs et al. JOURNAL OF THE NEUROLOGICAL SCIENCES
- A harmonized classification system for FTLD-TDP pathology
- (2011) Ian R. A. Mackenzie et al. ACTA NEUROPATHOLOGICA
- National Institute on Aging–Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease: a practical approach
- (2011) Thomas J. Montine et al. ACTA NEUROPATHOLOGICA
- The Alzheimer’s Association external quality control program for cerebrospinal fluid biomarkers
- (2011) Niklas Mattsson et al. Alzheimers & Dementia
- The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease
- (2011) Guy M. McKhann et al. Alzheimers & Dementia
- The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease
- (2011) Marilyn S. Albert et al. Alzheimers & Dementia
- Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: A consensus paper from the Alzheimer's Biomarkers Standardization Initiative
- (2011) Hugo Vanderstichele et al. Alzheimers & Dementia
- The Cerebrospinal Fluid Amyloid β42/40 Ratio in the Differentiation of Alzheimers Disease from Non-Alzheimers Dementia
- (2010) P.E. Spies et al. Current Alzheimer Research
- Tau and 14-3-3 of genetic and sporadic Creutzfeldt–Jakob disease patients in Israel
- (2010) Zeev Meiner et al. JOURNAL OF NEUROLOGY
- Cerebrospinal fluid and plasma biomarkers in Alzheimer disease
- (2010) Kaj Blennow et al. Nature Reviews Neurology
- Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update
- (2009) Ian R. A. Mackenzie et al. ACTA NEUROPATHOLOGICA
- Amyloid- (1-42), Total Tau, and Phosphorylated Tau as Cerebrospinal Fluid Biomarkers for the Diagnosis of Alzheimer Disease
- (2009) C. Mulder et al. CLINICAL CHEMISTRY
- CSF Biomarkers and Incipient Alzheimer Disease in Patients With Mild Cognitive Impairment
- (2009) Niklas Mattsson JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study
- (2009) Pieter Jelle Visser et al. LANCET NEUROLOGY
- Added diagnostic value of CSF biomarkers in differential dementia diagnosis
- (2009) Nathalie Le Bastard et al. NEUROBIOLOGY OF AGING
- Diagnostic performance of a CSF-biomarker panel in autopsy-confirmed dementia
- (2007) Sebastiaan Engelborghs et al. NEUROBIOLOGY OF AGING
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started